Status:
ENROLLING_BY_INVITATION
Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?
Lead Sponsor:
West Virginia University
Conditions:
Staphylococcus Aureus Bacteremia
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The goal of this open-label, pragmatic, randomized controlled clinical trial is to learn if patients with Staphylococcus aureus bacteremia (SAB) given the intervention of early dual intravenous (IV) a...
Eligibility Criteria
Inclusion
- The patient is hospitalized at J.W. Ruby Memorial Hospital, Berkeley Medical Center, Camden Clark Medical Center, Princeton Community Hospital, Thomas Hospital, United Hospital Center, or Wheeling Hospital
- The patient has been identified to have Staphylococcus aureus bacteremia
- The patient is able to participate in lab monitoring and in-person or telemedicine ID Clinic follow-up
Exclusion
- The patient or an appointed medical decision maker is unable to give informed consent
- The patient is a prisoner, pregnant, and/or mentally handicapped
- The patient is determined unsafe for enrollment at the primary team's discretion
Key Trial Info
Start Date :
September 15 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2027
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT07148960
Start Date
September 15 2025
End Date
July 1 2027
Last Update
September 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
West Virginia University
Morgantown, West Virginia, United States, 26506